HeartBeam (BEAT) Q3 2026 earnings review
HeartBeam cuts cash burn, but new share sales dilute owners
HeartBeam, the maker of a cable-free portable heart monitor, pivoted to heart attack testing while dropping talk of its initial rhythm-monitoring rollout. The company recorded zero revenue again, but third-quarter operating cash outflow fell 23% from the prior quarter to $2.6 million as device development wrapped up. Executive chairman Richard Ferrari cut the full-year cash burn plan to $12.0–12.5 million, which by our math leaves $2.7 million for the fourth quarter.
| Operating cash outflow | $2.6M down 23% from last quarter |
|---|---|
| Net loss | $3.0M $5.3M a year ago |
| Pro forma cash (including Q4 stock sales) | $10.1M $6.1M at September 30 |
| Full-year cash outflow outlook | Cut to $12.0–12.5M prior plan: below $14.0M |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because major regulatory progress on heart attack detection was offset by an abandoned commercial launch and heavy share dilution. Winning FDA Breakthrough status and a faster 510(k) review pathway makes the heart attack product much more realistic, and lower spending stretches cash into 2027. The bad news: management stayed silent on the concierge patient metrics it promised for this quarter and sold $4 million of new stock after quarter-end, lifting diluted shares 66% from a year ago.
The question now is whether HeartBeam can finish its U.S. pivotal heart attack study before needing another dilutive stock sale. One view is that the $10.1 million pro forma cash balance and a smaller 510(k) trial design will fund the company to FDA submission; the other is that starting enrollment in the first quarter of 2027 will push spending back up and force another raise. The final pivotal study design and trial budget in the fourth quarter will tell.
🐂 Bull Case
FDA Cleared the Path for Home Heart Attack Testing
HeartBeam makes a credit-card-sized device that records heart signals without cables and turns them into a 12-lead electrocardiogram (ECG), the standard wiring test hospitals use. In October, the Food and Drug Administration (FDA) agreed to review the system under a 510(k) submission, a faster regulatory pathway that compares a new device with one already on the market.
The agency also granted Breakthrough Device Designation in under 30 days for "a tool for assessing potential heart attacks at home". At a medical conference, the company shared data from ALIGN-ACS, a 132-patient emergency room study in Serbia.
- Specificity (ruling out false alarms): 81.8% for HeartBeam versus 71.4% for a standard 12-lead ECG
- Sensitivity (catching true events): 60.2% versus 63.0% for a standard 12-lead ECG
- Doctor agreement (Fleiss' kappa, a consistency score): 0.73 versus 0.54 for a standard 12-lead ECG
- Patient self-use: 100% of patients recorded their own test without prior training
This matters because the 510(k) agreement removes the risk that regulators demand a massive multi-year trial, whileexecutive chairman Richard Ferrari noted there is "no new hardware required". What to watch: the final U.S. pivotal study patient count in the fourth quarter, because a small sample size will keep trial costs down.
Cash Burn Dropped After Device Work Wrapped Up
HeartBeam has no revenue, so its survival depends on how quickly it spends cash. In the third quarter, the cash it used for daily operations fell 23% from the second quarter to $2.6 million, beating its own plan to keep spending near $3.3 million. Net loss narrowed to $3.0 million from $5.3 million a year ago.
Research and development costs dropped 35% from a year ago to $2.1 million on "the completion of product development and consulting costs related to the HeartBeam System and a prototype patch device" ($0.8 million) and finishing the Serbian pilot study ($0.3 million). General and administrative costs fell 33% to $1.3 million on lower headcount and stock pay.
Management cut its full-year cash outflow plan for a third straight quarter. What to watch: fourth-quarter operating cash outflow against the $2.5 million baseline, because staying near that level proves the lower cost structure will hold once the U.S. clinical trial begins.
Global Studies Expanded Without Heavy Spending
To win over doctors and regulators, HeartBeam needs clinical evidence across hundreds of chest-pain patients. In October, the medical device maker finished enrolling 486 emergency room patients ahead of schedule in HEADSTART-ACS, a heart attack study at Indonesia's national heart center. Combined with the Serbian pilot, its technology has now been tested in over 600 patients.
The company also joined EXIT-CVD, a research group co-funded by the European Union that includes Philips, Medtronic, and GE HealthCare. HeartBeam will lead HEART-CHECK, one of the group's 22 clinical studies, to test its device in high-risk patients recently sent home from the hospital. Outside funding lets the company build clinical proof without draining its own cash.
What to watch: diagnostic accuracy data from the 486-patient Indonesian study in early 2027. Matching the 81.8% specificity from the smaller Serbian trial would validate the software across a much larger patient group.
🐻 Bear Case
HeartBeam Quietly Walked Away From Its Concierge Launch
"The third quarter marked a decisive turn for HeartBeam," executive chairman Richard Ferrari said, as the company "directed the majority of its financial and personnel resources to heart attack assessment". Last quarter, management promised that commercial orders from concierge doctors for its rhythm-monitoring tool would grow by the end of the third quarter, when it would begin sharing patient counts.
Instead, the third-quarter income statement showed zero revenue again, and the press release dropped all mention of concierge practices, commercial orders, and active patients. While management frames the pivot as chasing a $15 billion heart attack market that is four times larger than rhythm monitoring, the silence confirms the initial commercial rollout did not gain traction.
Because the company needs roughly 30,000 paying patients to break even, abandoning the commercial push leaves it with no near-term cash inflows. What to watch: any mention of active paying patients or subscription cash receipts in the quarterly filing, because another zero confirms the company will remain pre-revenue until after FDA heart attack clearance.
New Share Sales Paid for the Extended Cash Runway
HeartBeam ended September with $6.1 million in cash and cash equivalents, down from $8.7 million in June. To fund operations, the company signed an at-the-market (ATM) agreement with Titan Partners in August, allowing it to sell up to $25 million of common stock directly into the public market.
Between October 1 and November 12, the device maker raised $4.0 million in net cash through that facility, lifting its pro forma September cash balance to $10.1 million. That sale, following an $11.5 million stock offering in April, pushed weighted-average diluted shares up 66.3% from a year ago to 57.2 million.
The company did not disclose the price or share count for the fourth-quarter $4.0 million raise, which shrinks each existing shareholder's stake in future clinical success. What to watch: the exact post-September share count in the third-quarter 10-Q filing, which will reveal the price per share of the recent $4.0 million stock sale.
The Pivotal Trial Slipped Into Next Year
Winning FDA clearance for home heart attack testing requires a U.S. pivotal clinical study. Last quarter, leadership expressed hope that the trial could begin before the end of 2026. Now, Ferrari says the team is focused on "beginning our U.S. pivotal study in the first quarter of 2027", using the fourth quarter to finalize the trial design with regulators.
Even with the enrollment start pushed into next year, the company warned that "accelerated U.S. pivotal study timing would add to fourth quarter spending". By our math, the new full-year cash outflow outlook of $12.0 million to $12.5 million minus the $9.5 million spent in the first nine months implies $2.5 million to $3.0 million of fourth-quarter cash burn, above the $2.5 million baseline.
What to watch: announcement of the first patient enrolled in the U.S. pivotal trial in the first quarter of 2027. Any further delay would push FDA submission and commercial revenue deeper into 2028.
Risks this quarter didn't answer
Three standing governance, listing, and partnership concerns received no update in the third-quarter press release.
- Nasdaq listing compliance: no update on the December 29, 2026 deadline to cure the minimum bid-price deficiency or whether a reverse stock split is planned.
- Permanent chief executive: no timeline for naming a permanent chief executive after Robert Eno's June departure; founder Branislav Vajdic and executive chairman Richard Ferrari continue to co-lead.
- Extended-wear patch partner: no commercial partner announced for the 12-lead patch device, and research spending on the prototype wound down during the quarter.
👓 Other Themes
FDA Program Opens Early Talks With Medicare
In October, the FDA accepted the HeartBeam System into its Total Product Life Cycle Advisory Program (TAP). The regulatory initiative provides dedicated agency advisors and "early engagement with payers, including the Centers for Medicare & Medicaid Services". Because shifting from concierge cash-pay clinics to a broad 20-million-patient heart attack market requires insurance coverage, early payer discussions help align the upcoming pivotal trial with reimbursement standards.
💲 Other KPIs
Unpaid bills and accrued liabilities fell 58.1% from $3.24 million at the end of 2025 to $1.36 million in September, down from $2.46 million in June. Paying down these short-term obligations consumed $1.88 million of operating cash over the first nine months of 2026 as clinical and device development contracts wrapped up.
By our math, non-cash employee stock pay was $0.94 million in the third quarter ($3.86 million for the nine months minus $2.92 million in the first half), or 27.1% of total operating expenses. That is down $0.4 million in general and administrative lines from a year ago and down from the second quarter, which included $0.6 million of former chief executive exit charges.
🔮 Guidance
Improved. The company lowered its full-year cash burn target to $12.0–12.5 million, its third cut after starting the year at $17.0–19.0 million and moving to below $16.0 million, then below $14.0 million. By our math, subtracting $9.54 million spent in the first nine months leaves $2.46–2.96 million for the fourth quarter ($2.71 million at the middle of the range, up 4.7% from the third quarter).
Unchanged. Management kept its fourth-quarter baseline cash burn ceiling below $2.5 million, down from $2.59 million in the third quarter. However, the outlook notes that preparing for the U.S. pivotal heart attack study will add to fourth-quarter spending above that baseline, which aligns with the $2.46–2.96 million implied by the full-year range.
❓ Key Questions
What happened to the concierge cardiology rollout and patient metrics?
Last quarter, management promised that concierge device orders would grow by the end of the third quarter and that patient counts would follow. This release reported zero revenue and never mentioned the concierge channel.
At what price were shares sold in the $4.0M raise?
HeartBeam raised $4.0 million in net cash through its at-the-market stock facility after September 30, but did not disclose how many shares it issued or the average sale price.
How will HeartBeam cure its Nasdaq minimum bid deficiency?
The company faces a December 29, 2026 deadline to bring its share price back above $1.00 for Nasdaq compliance, and the release gave no update on reverse-split plans.
How many patients and how much cash will the pivotal trial require?
With FDA alignment on a 510(k) pathway now in hand and enrollment set for the first quarter of 2027, investors need the trial's patient target, duration, and total budget.